Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

By G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, N. Gebbia, G. Cartenì, B. Agostara, G. Pezzella, L. Manzione and 25 more. Journal of Clinical Oncology, 2005

724 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/5b0a971b59aced4b18a55a8ba7d83e7b392d0f22

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Masi
2. E. Pfanner
3. Raoudha Soufi-Mahjoubi
4. L. Fanchini
5. G. Porcile
6. S. Ricci
7. G. Benedetti
8. J. Marshall

Citations in the corpus

• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007, background): “Furthermore, comparisons of FOLFOX with FOLFIRI in randomized studies have reported equivalent activity and efficacy.(8,26) The Hellenic Oncology Research Group (HORG) reported the results of a study comparing FOLFIRI to a combination of FU, CPT11, and LOHP.”
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. (2007, result): “In a previous Intergroup study of first-line therapy for metastatic colorectal cancer (N9741), an infusional schedule of FU/LV with oxaliplatin (FOLFOX) provided superior efficacy to a bolus schedule of IFL(13); in contrast, studies comparing FOLFOX with FOLFIRI demonstrated similar efficacy.(14,15)”